Dr. Gilberto Lopes, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 102
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME85706
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 102
- Services billed
- 519
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 154 | 60 |
| Established patient office or other outpatient visit, 20-29 minutes | 53 | 32 |
| Established patient office or other outpatient visit, 40-54 minutes | 24 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Miami, FL | 34 |
| Doxycycline Hyclate Other prescribers in Miami, FL | 31 |
| Eliquis (apixaban) Other prescribers in Miami, FL | 30 |
| Levothyroxine Sodium Other prescribers in Miami, FL | 30 |
| Ondansetron Odt (ondansetron) Other prescribers in Miami, FL | 27 |
| Alecensa (alectinib hcl) | 27 |
| Tagrisso (osimertinib mesylate) | 25 |
| Atorvastatin Calcium Other prescribers in Miami, FL | 23 |
| Metformin Hcl Other prescribers in Miami, FL | 22 |
| Ibuprofen Other prescribers in Miami, FL | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 14 payments worth $28,812 in total to this clinician.
| Merck Sharp & Dohme LLC | $11,200 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $7,873 |
| Dr.reddy's Laboratories,inc. | $3,750 |
| Beone Medicines USA, Inc. | $3,750 |
| Janssen Global Services, LLC | $1,350 |
| Rigel Pharmaceuticals, Inc. | $685 |
| Janssen Biotech, Inc. | $204 |
| Consulting Fee | $15,405 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $12,710 |
| Travel and Lodging | $417 |
| Food and Beverage | $280 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 1, 2025 | Consulting Fee TAGRISSO · Oncology | $6,560 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Merck Sharp & Dohme LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Dr.reddy's Laboratories,inc. Nov 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,750 |
| Beone Medicines USA, Inc. Jun 27, 2025 | Consulting Fee | $2,250 |
| Merck Sharp & Dohme LLC May 5, 2025 | Consulting Fee | $2,240 |
| Beone Medicines USA, Inc. Apr 18, 2025 | Consulting Fee | $1,500 |
| Janssen Global Services, LLC Mar 27, 2025 | Consulting Fee RYBREVANT · Oncology | $1,350 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Consulting Fee TAGRISSO · Oncology | $820 |
| Rigel Pharmaceuticals, Inc. Feb 9, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $685 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Dr.reddy's Laboratories,inc. Nov 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,750 |
| Merck Sharp & Dohme LLC Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Beone Medicines USA, Inc. Jun 27, 2025 | Consulting Fee | $2,250 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Consulting Fee TAGRISSO · Oncology | $820 |
| Merck Sharp & Dohme LLC May 5, 2025 | Consulting Fee | $2,240 |
| Beone Medicines USA, Inc. Apr 18, 2025 | Consulting Fee | $1,500 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| AstraZeneca Pharmaceuticals LP Apr 1, 2025 | Consulting Fee TAGRISSO · Oncology | $6,560 |
| Janssen Global Services, LLC Mar 27, 2025 | Consulting Fee RYBREVANT · Oncology | $1,350 |
| AstraZeneca Pharmaceuticals LP Mar 17, 2025 | Travel and Lodging travel to Orlando, FL · in-kind Company’s descriptionSpeaker Expenses | $417 |
| Rigel Pharmaceuticals, Inc. Feb 9, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $685 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $528,913 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Beigene, Ltd. · Recruiting · NCT05981703 - A phase 1 openlabel dose escalation and dose expansion study to evaluate the safety tolerability pharmacokinetics and anti tumor activity of PF07799933 ARRY440 as a single agent and in combination therapy in participa…
Pfizer Inc. - BLU667 1101 ARROW ongoing
Hoffmann-la Roche Limited - A phase 1B/2A pilot study to evaluate the safety and tolerability of a
GlaxoSmithKline, LLC. - A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06618287
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.